Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jin Seok Kim, Seong Kyu Park, Hyo Jung Kim, Jeeyun Lee, Baek Yeol Ryoo, Young Hyeh Ko, Jooryung Huh, Woo Ick Yang, Hee Kyung Kim, Soo Kee Min, Seung Sook Lee, In Gu Do, Cheolwon Suh, Won Seog Kim

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: We performed a phase II study to evaluate the efficacy of bortezomib in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas (PTCLs) based on our phase I study results. Methods: Patients received bortezomib on days 1 and 8 at a dose of 1.6 mg/m2 in addition to CHOP every 3 weeks for a total of six cycles. Results: Forty-six patients were enrolled: PTCL, not otherwise specified (PTCL-NOS, n = 16), extranodal NK/T-cell lymphoma, nasal type (ENKTL, n = 10), angioimmunoblastic T-cell lymphoma (AITL, n = 8), ALK-negative anaplastic large-cell lymphoma (ALCL, n = 6), cutaneous T-cell lymphoma (CTCL, n = 5) and hepatosplenic T-cell lymphoma (n = 1). Thirty patients achieved complete response (CR, 65%) and the overall response rate was 76% (35/46). Although the CR rate of ENKTL was only 30% (3/10), three subtypes of PTCLs (PTCL-NOS, AITL and ALCL) showed 87% of overall response rate (ORR) (26/30) and 73% of CR rate (22/30). However, the 3-year overall survival and progression-free survival were 47% and 35%, respectively due to frequent relapse after remission. Grade 3/4 leucopenia was the most frequent toxicity whereas neurotoxicity was tolerable: grade 1 or 2 of peripheral neuropathy. Conclusions: The combined treatment of bortezomib and CHOP is an effective and feasible regimen for advanced-stage PTCLs other than ENKTL, with acceptable toxicity. However, future studies exploring new drug combinations are warranted to overcome relapse after remission.

Original languageEnglish
Pages (from-to)3223-3231
Number of pages9
JournalEuropean Journal of Cancer
Volume48
Issue number17
DOIs
Publication statusPublished - 2012 Nov 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, S. J., Yoon, D. H., Kang, H. J., Kim, J. S., Park, S. K., Kim, H. J., Lee, J., Ryoo, B. Y., Ko, Y. H., Huh, J., Yang, W. I., Kim, H. K., Min, S. K., Lee, S. S., Do, I. G., Suh, C., & Kim, W. S. (2012). Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. European Journal of Cancer, 48(17), 3223-3231. https://doi.org/10.1016/j.ejca.2012.06.003